Errol B. Desouza - Nov 30, 2023 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Role: Director
Signature: /s/ ERROL B DESOUZA
Stock symbol: CYCN
Transactions as of: Nov 30, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/4/2023, 04:05 PM
Previous filing: Jun 26, 2023
Next filing: Mar 21, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYCN	Common Stock	Award	$0	+20K	+66.67%	$0.00	50K	Nov 30, 2023	Direct	F1
transaction	CYCN	Common Stock	Award	$0	+30K		$0.00	30K	Nov 30, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
F2	The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

Content

The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.